- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06028022
Reishi-paddenstoelextract voor vermoeidheid en/of artralgie/myalgie bij patiënten met borstkanker die aromataseremmers gebruiken
Reishi-paddenstoelextract voor vermoeidheid en/of gewrichtspijn bij patiënten met borstkanker die aromataseremmers gebruiken: een gerandomiseerde fase II MNCCTN-studie
This phase II trial tests how well Reishi mushroom extract works in treating fatigue and/or joint/muscle pain (arthralgias/myalgias) in patients with breast cancer on aromatase inhibitors. Fatigue and arthralgias/myalgias are common symptoms in breast cancer patients taking aromatase inhibitors (AI). Given the long duration of AI treatment for some women (up to 10 years), these symptoms can significantly impact quality of life and premature discontinuation of AIs, a beneficial medication. Reishi mushrooms are among several medicinal mushrooms that have been used for hundreds of years, mainly in Asian countries, to help enhance the immune system, reduce stress, improve sleep, and lessen fatigue. Reishi mushroom extracts have not been studied explicitly for treatment-induced arthralgias/myalgias, but have been shown to improve quality of life, muscular strength, pain, and flexibility. Information from this study may help researchers determine the effect of Reishi mushroom extract on fatigue and arthralgias/myalgias in breast cancer patients receiving an AI.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To evaluate the efficacy of 1,000 mg three times daily (TID) of Reishi mushroom extracts as therapy for cancer-related fatigue measured by uniscale measurement at the end of four weeks.
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of Reishi mushroom extracts as therapy for cancer-related arthralgias at the end of four weeks and four weeks after cross-over as measured by the Brief Pain index (BPI)-adapted for AI associated arthralgias.
II. To evaluate the effect of Reishi mushroom extracts on cancer-related quality of life (QOL), as measured by uniscale, at the end of four weeks and four weeks after cross-over.
III. To evaluate the efficacy of Reishi mushroom extracts on mood, as assessed by the World Health Organization Five Well-Being Index (WHO-5) item well-being scale, at the end of four weeks and four weeks after cross-over.
IV. To evaluate treatment toxicity between the two treatment arms, as measured by a patient symptom experience diary and weekly calls from the study team.
V. To evaluate the interest, knowledge, and acceptance of integrative treatments for cancer-related symptoms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive Reishi mushroom extract orally (PO) TID on days 1-28 for weeks 1-4 and then placebo PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive placebo PO TID on days 1-28 for weeks 1-4 and Reishi mushroom extract PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Clinical Trials Referral Office
- Telefoonnummer: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
Studie Locaties
-
-
Minnesota
-
Albert Lea, Minnesota, Verenigde Staten, 56007
- Actief, niet wervend
- Mayo Clinic Health System in Albert Lea
-
Baxter, Minnesota, Verenigde Staten, 56425
- Actief, niet wervend
- Essentia Health Baxter Clinic
-
Bemidji, Minnesota, Verenigde Staten, 56601
- Actief, niet wervend
- Sanford Joe Lueken Cancer Center
-
Brainerd, Minnesota, Verenigde Staten, 56401
- Actief, niet wervend
- Essentia Health Saint Joseph's Medical Center
-
Deer River, Minnesota, Verenigde Staten, 56636
- Actief, niet wervend
- Essentia Health Deer River Clinic
-
Detroit Lakes, Minnesota, Verenigde Staten, 56501
- Actief, niet wervend
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth, Minnesota, Verenigde Staten, 55805
- Actief, niet wervend
- Essentia Health Cancer Center
-
Ely, Minnesota, Verenigde Staten, 55731
- Actief, niet wervend
- Essentia Health Ely Clinic
-
Fosston, Minnesota, Verenigde Staten, 56542
- Actief, niet wervend
- Essentia Health Fosston
-
Grand Rapids, Minnesota, Verenigde Staten, 55744
- Actief, niet wervend
- Fairview Grand Itasca Clinic & Hospital
-
Hibbing, Minnesota, Verenigde Staten, 55746
- Actief, niet wervend
- Essentia Health Hibbing Clinic
-
Hibbing, Minnesota, Verenigde Staten, 55746
- Actief, niet wervend
- Fairview Range Medical Center
-
International Falls, Minnesota, Verenigde Staten, 56649
- Actief, niet wervend
- Essentia Health International Falls Clinic
-
Mankato, Minnesota, Verenigde Staten, 56001
- Actief, niet wervend
- Mayo Clinic Health Systems-Mankato
-
Monticello, Minnesota, Verenigde Staten, 55362
- Ingetrokken
- MMCORC CentraCare Monticello Cancer Center
-
Moose Lake, Minnesota, Verenigde Staten, 55767
- Actief, niet wervend
- Essentia Health Moose Lake
-
Park Rapids, Minnesota, Verenigde Staten, 56470
- Actief, niet wervend
- Essentia Health Park Rapids
-
Princeton, Minnesota, Verenigde Staten, 55731
- Actief, niet wervend
- Fairview Northland Medical Center
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Mayo Clinic in Rochester
-
Hoofdonderzoeker:
- Stacy D. D'Andre, M.D.
-
Contact:
- Clinical Trials Referral Office
- Telefoonnummer: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Sandstone, Minnesota, Verenigde Staten, 55072
- Actief, niet wervend
- Essentia Health Sandstone
-
Thief River Falls, Minnesota, Verenigde Staten, 56701
- Actief, niet wervend
- Sanford Thief River Falls Medical Center
-
Virginia, Minnesota, Verenigde Staten, 55792
- Actief, niet wervend
- Essentia Health Virginia Clinic
-
Worthington, Minnesota, Verenigde Staten, 56187
- Actief, niet wervend
- Sanford Worthington Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥ 18 years
- History of breast cancer, estrogen receptor positive (ER+), Her 2 positive or negative
- Fatigue ≥ 4/10
- Currently post-menopausal (as defined by National Comprehensive Cancer Network (version 4.2024), taking any aromatase inhibitor in the curative setting and planning to be on such for at least 8 weeks after registration. [Patients on concurrent ovarian suppression (such as with leuprolide acetate, goserelin) are allowed]; CDK 4/6 inhibitors abemaciclib, ribociclib ARE allowed
- Prior treatment: last chemotherapy ≥ 90 days prior to randomization (if treated with chemotherapy)
- On a stable dose of pain medications if pain medications are being regularly used. (i.e., no change in dosage in the past 30 days)
- If on supplements, must be on stable dose with no plan to change; not on or planning any acupuncture or other specific supportive modalities for fatigue or AI arthralgias
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
- White blood cell count (WBC) ≥ 3,000/mm^3 (obtained ≤ 30 days prior to randomization)
- Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to randomization)
- Platelet count ≥ 100,000/mm^3 (obtained ≤ 30 days prior to randomization)
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 30 days prior to randomization)
- Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 1.2 x ULN (obtained ≤ 30 days prior to randomization)
- Prothrombin time (PT)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (obtained ≤ 30 days prior to randomization)
- Negative pregnancy test done ≤ 7 days prior to registration, for persons on concurrent ovarian suppression only
- Provide informed consent
- Ability to complete questionnaires
- Willing to return to enrolling institution during the active monitoring phase of the study
- Patients who have had a recent surgery or procedure should be healed and cleared by their clinician and/or surgeon per local standards, prior to registration
Exclusion Criteria:
-
Other known uncontrolled medical conditions causing fatigue such as untreated thyroid disease, depression, fibromyalgia, chronic fatigue syndrome, infection, autoimmune disease, or active/untreated hepatitis
-
Allergy to mushrooms
-
On anticoagulation medication or aspirin or having a known bleeding disorder
-
On any specific medication for fatigue (e.g., methylphenidate)
-
Metastatic cancer diagnosis (history of nodal metastases is allowed)
-
Chronic steroid use, unless on physiologic replacement doses
-
Current use of any medical mushrooms
-
On medications for diabetes
-
History of symptomatic hypotension
-
Taking CYP3A4, CYP2D6 sensitive substrates which can be located at the following link: https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems
-
Drugs which exhibit either >20% inhibition or >20% induction of CYP2E1 in vivo, such as: Acetaminophen, Dapsone, Enflurane, Halothane, Isoflurane, & Theophylline
-
Taking olaparib
-
Any of the following because this study involves an agent that has unknown genotoxic, mutagenic and teratogenic effects:
- Pregnant persons
- Nursing persons
- Persons on concurrent ovarian suppression who are unwilling to employ adequate contraception (e.g., hormonal methods, barrier methods, intrauterine device, abstinence)
-
Planned surgery or procedure during time on study and ≤ 14 days after last dose, due to bleeding risks
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm I (Reishi mushroom extract, placebo)
Patients receive Reishi mushroom extract PO TID on days 1-28 for weeks 1-4 and then placebo PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity. |
Ancillary studies
Andere namen:
Ancillary studies Given PO Given Reishi mushroom extract PO
Andere namen:
|
|
Experimenteel: Arm II (placebo, Reishi mushroom extract)
Patients receive placebo PO TID on days 1-28 for weeks 1-4 and Reishi mushroom extract PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity. |
Ancillary studies
Andere namen:
Ancillary studies Given PO Given Reishi mushroom extract PO
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in fatigue scores
Tijdsspanne: Baseline to end of four weeks
|
Based on a single item fatigue uniscale question. Will be compared between arms using a two-sided two-sample t-test assuming equal variances in each group. |
Baseline to end of four weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in quality of life
Tijdsspanne: Baseline to the end of four weeks and four weeks after cross-over
|
Measured by the World Health Organization-Five Well-Being Index. Will be compared between arms using two-sample, two-sided t-tests assuming equal variances and alpha levels of 5%. The analyses of the crossover portion of the study will be descriptive. Mean values will be plotted over time by arm. A formal crossover analysis will also be performed using Senn's linear modeling approach. |
Baseline to the end of four weeks and four weeks after cross-over
|
|
Change in arthralgias
Tijdsspanne: Baseline to the end of four weeks and four weeks after cross-over
|
Measured by the Brief Pain Inventory for Aromatase Inhibitor Induced Arthralgia. Will be compared between arms using two-sample, two-sided t-tests assuming equal variances and alpha levels of 5%. The analyses of the crossover portion of the study will be descriptive. Mean values will be plotted over time by arm. A formal crossover analysis will also be performed using Senn's linear modeling approach. |
Baseline to the end of four weeks and four weeks after cross-over
|
|
Incidence of adverse events
Tijdsspanne: Up to 30 days follow-up
|
Measured by the symptom experience diary. Will be compared between arms using two-sample, two-sided t-tests assuming equal variances and alpha levels of 5%. The analyses of the crossover portion of the study will be descriptive. Mean values will be plotted over time by arm. A formal crossover analysis will also be performed using Senn's linear modeling approach. |
Up to 30 days follow-up
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Stacy D. D'Andre, MD, Mayo Clinic in Rochester
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- MC221002
- MC221002 (Andere identificatie: Mayo Clinic in Rochester)
- NCI-2023-06578 (Register-ID: CTRP (Clinical Trials Reporting Program))
- 23-005266 (Andere identificatie: Mayo Clinic Institutional Review Board)
- MNCCTN032 (Andere identificatie: Minnesota Cancer Clinical Trials Network)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .